StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities researchers at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Down 1.8 %

NYSE NBY opened at $0.63 on Monday. The business has a 50 day moving average price of $0.66 and a 200-day moving average price of $0.63. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $9.08. The company has a market cap of $3.08 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.